Close menu




April 20th, 2022 | 10:29 CEST

The million-dollar opportunity: Valneva, Edgemont Gold, BASF

  • Gold
  • Copper
  • Biotechnology
Photo credits: pixabay.com

No one can see into the future. But investors can estimate which topics will move share prices in the near future. There is not always a connection between what is important and what is played out in the media. Issues such as climate change are timeless but disappear from the front pages from time to time. It is currently a similar situation with the pandemic. We dare to take a look into the future and ask what could move prices this summer.

time to read: 3 minutes | Author: Nico Popp
ISIN: VALNEVA SE EO -_15 | FR0004056851 , EDGEMONT GOLD CORP. O.N. | CA28008L1067 , BASF SE NA O.N. | DE000BASF111

Table of contents:


    Ryan Jackson, CEO, Newlox Gold Ventures Corp.
    "[...] We quickly learned that the tailings are high-grade, often as high as 20 grams of gold per tonne; because they are produced by artisanal miners, local miners who use outdated technology for gold production. [...]" Ryan Jackson, CEO, Newlox Gold Ventures Corp.

    Full interview

     

    Valneva: The air is out

    Incidences in Germany are on the decline. Nevertheless, values around 800 still feel like a lot. But the topic has lost its way. Almost everyone has had Corona. In most cases, the disease was mild. That takes away the horror of the incidence. The immunity that now exists also ensures that hardly any patients have to be hospitalized. Nevertheless, experts warn about the coming fall. Vaccination rates are still too low to prevent hospitals from being overburdened. There are also more and more mutants, which could become more dangerous. But what good is speculation at a time when people are pandemic-weary and anything but fearful?

    Most recently, Health Minister Karl Lauterbach used the word "killer variant". It is not only critics of the Corona policy who are reacting badly to this, and not without good reason. After years of the pandemic and many warnings - some exaggerated - only very few people have an open ear for such warnings. The pandemic theme will level off in the coming months. Titles such as Valneva are still on an upward trend, but the air is out. Even the initial approval of the Corona vaccine in the UK did not cause Valneva to make any significant leaps. The fact that this is an inactivated whole-virus vaccine and, in relation to Corona, an innovation, is now of little interest to anyone.

    Edgemont Gold: EUR 1 million market capitalization and a clear goal

    Looking at the share price of gold and copper company Edgemont Gold, one could draw parallels to CureVac's vaccine failure. Edgemont Gold's stock has dropped a whopping 62% in the past month. What happened? In late March, Edgemont Gold announced drill results. The team drilled 27 meters of gold grading 0.44 g/t, including a six-meter interval of 1.26 g/t gold. However, the results were less encouraging for copper and did not reveal any higher grade concentrations greater than 0.2%. The market had expected this and has since punished the stock. However, the Company itself stresses that the results to date are a template for further drilling. "With the assay results in hand, we are excited to finalize our drill plan and begin our Phase II drill program next month," said Stuart Rogers, president and CEO.

    Since exploration drilling always provides clues to the composition of rocks and the underlying geology of a project, in addition to concrete grades, even the upcoming drilling could provide more encouraging results for copper. In any case, exploration projects are subject to constant ups and downs and are therefore suitable for anti-cyclical investors. With a market capitalization of around EUR 1 million, Edgemont Gold is now an exciting warrant on the two trend themes of gold and copper. Positive drill results are likely to awaken new potential and boost the value. However, the share must be considered extremely speculative.

    BASF: Risks despite foresight

    BASF shows that risk is sometimes assessed in a distorted way on the stock market. The chemical giant from Ludwigshafen is suffering from the general situation. If the war in Ukraine continues to escalate and sanctions are extended, BASF could soon run out of energy. Since BASF makes a decisive contribution to the global supply of fertilizers, the situation is doubly critical. In addition to share price losses, there is a threat of hunger in many regions of the world in the long term. The share is currently showing little momentum. Below EUR 50, there is a threat of further share price losses; a comeback awaits beyond EUR 55. In between, the stock is a hot potato. But if BASF comes through the current crisis, the Company could benefit in the long term. After all, the Company had already presented a concept to move away from fossil fuels before the war.


    The current market situation is challenging for investors. Even well-positioned companies like BASF could go under the radar. Former hopefuls, such as Valneva, are also moving more and more out of focus. In the end, those companies that solve acute problems are likely to profit. These include stocks from the energy and commodities sectors. Edgemont Gold has been penalized for drilling results, although further drilling is still planned for the end of April, building on previous findings. The stock is down. The Company is worth about EUR 1 million. Cash on hand was EUR 1.2 million in February. It may be an opportunity.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Nico Popp on January 30th, 2026 | 07:25 CET

    The hunt for the cancer pill from BioNTech & Co.: Why Eli Lilly's billion-dollar bet is a wake-up call for Vidac Pharma

    • Biotechnology
    • Biotech
    • Pharma
    • Cancer

    It is one of the oldest rules in the biotech sector: when the big pharmaceutical companies can no longer grow on their own, they open their coffers. The latest billion-dollar deal between US giant Eli Lilly and Dresden-based startup Seamless Therapeutics is more than just a headline – it is a wake-up call for the entire industry. Eli Lilly, now one of the most valuable companies in the world, is desperately seeking innovations to secure its pipeline beyond its booming weight-loss injections. This hunger for new mechanisms of action inevitably focuses attention on small, specialized companies researching revolutionary approaches. In this environment, Vidac Pharma is becoming the focus of strategic investors. The Company is working on an approach that is as elegant as it is radical: it aims to starve cancer rather than poison it by manipulating its metabolism. While Eli Lilly and BioNTech are spreading their billions across a wide range of areas, Vidac is delivering precisely the kind of specialized "deep science" that is often lacking in the pipelines of the big players.

    Read

    Commented by Fabian Lorenz on January 29th, 2026 | 07:00 CET

    Puma takeover is becoming more concrete! Should investors buy Evotec and Silver Viper shares next?

    • Mining
    • Silver
    • Commodities
    • Biotechnology
    • Sportswear
    • Takeover

    Takeover speculation has been swirling around Puma for some time. Now it has become more tangible: Anta has secured a 29% stake in the German sporting goods group, paying EUR 35 per share. However, the euphoria on the stock market is limited. Are there better opportunities for investors to profit from takeover speculation? One candidate in the hot silver market is Silver Viper. The Company is pushing ahead with exciting projects in Mexico. Its recent capital increase met with strong demand, and a financially powerful potential buyer already has a foot in the door. And what about Evotec? The perennial takeover candidate is still not gaining momentum. That said, the biotech company is benefiting from the sale of one of its own holdings, which is expected to bring in around USD 160 million.

    Read

    Commented by Carsten Mainitz on January 27th, 2026 | 07:20 CET

    Let profits run: Power Metallic Mines, Barrick Mining, and TKMS – There is still a lot of potential here!

    • Mining
    • PGEs
    • Gold
    • Silver
    • Commodities
    • CriticalMetals
    • Defense

    The bull market for precious metals is gaining momentum. Gold and silver reached new historic highs with prices above USD 5,000 and USD 100 per troy ounce. Prices for critical raw materials and industrial metals are also rising. This is fueling further price increases for precious metal and commodity producers such as Barrick Mining. Up-and-coming producers such as Power Metallic Mines, whose assets have strategic value due to their jurisdiction, size, and quality, also offer promising opportunities. In addition, defense stocks continue to be popular with investors.

    Read